SK Capital Partners has acquired a majority stake in Halo Pharmaceutical for an undisclosed amount.

Halo, headquartered in Whippany, New Jersey, provides outsourced development and manufacturing services to the pharmaceutical industry.  The company makes solid, semi-solid and liquid medicines, with a particular focus on controlled substances.

SK Capital, a New York private equity firm, expects the investment to help Halo grow organically and through acquisitions. The firm closed a $1 billion fund in December. Before that, in October, SK portfolio company Anchroma agreed to buy the textile operations of BASF SE (FRA: BAS). 

Many pharmaceutical companies have looked to outsource manufacturing as they focus more on drug development. For more on pharmaceutical manufacturing, see Pursuing Pharmaceutical Manufacturing

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.